Q2
ALT — Q2 2026 Financial Report Analysis
Altimmune raised $281 million in two 2026 stock sales, ending June with $518.6 million in cash and investments as its Phase 3 MASH trial began; the Q2 net loss was $22.8 million, and a doubled share count cut loss per share to $0.12.